Approval for new FIC depression drug on the horizon!
Apparatus
-
-
Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!
-
The global ADC drug market will be approximately $5.2 billion by 2021
-
Recently, Nassim Annabi, an assistant professor of Northeastern University in the United States, and other researchers from the University of Sydney in Australia jointly developed an advanced surgical glue MeTro. When using, the glue directly enters the wound and is solidified and sealed within 60 seconds. Naxim said, "The advantage of MeTro formula is that once it touches the organ, it will appear as gel instantly and will not slip."
-
Apparatus
Angry FDA & CDC: $5 Billion Bivalent Moderna New Crown Vaccine Not As Effective As Monovalent
Was the omission of key data intentional or unintentional?
-
Apparatus
The "hand speed" is extremely fast, and scientists create a DNA robot arm that can move at a high speed
DNA nano robot system is one of the nano machines, and has been continuously developed in recent years. In recent years, in the journal Science, we saw another "feat" realized by DNA nano robot - researchers used electric field to accelerate the movement speed of DNA robot system.
-
Apparatus
Nature Medicine publishes results of H-drug combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma
H-Drugs in the leading international journal again!
-
Apparatus
Hutchison Pharmaceuticals Announces Approval Of Cd73 Monoclonal Antibody Mupadolimab In Phase I/Ib Clinical Trial In China
The Phase I/Ib clinical trial of Mupadolimab, a humanized monoclonal antibody against CD73 and its combination with pablizumab, has received clinical trial approval from the NMPA Pharmacovigilance Center for use in patients with advanced solid tumors.
-
Apparatus
Heavyweight! First ADC Drug For Refractory Ovarian Cancer Receives Accelerated FDA Approval
Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.
-
New therapy for lung cancer!